论文部分内容阅读
目的探讨骨形态发生蛋白-2(BMP-2)在卵巢癌患者血清中的表达及意义。方法采用酶联免疫吸附法(ELISA)检测51例恶性卵巢肿瘤患者血清中BMP-2和癌抗原125(CA125)的表达,另选取49名健康女性作为对照。结果卵巢上皮癌血清中BMP-2的表达水平明显低于对照组[(26.66±8.68)pg/ml vs(39.34±7.62)pg/ml],差异有统计学意义(P<0.05)。ROC曲线分析显示血清BMP-2的检测具有较好的敏感度和特异度。相关性分析显示血清中BMP-2的表达与CA125呈负相关(r=-0.76,P<0.05)。结论卵巢癌患者血清中BMP-2表达下调,对临床诊断有重要的参考价值。
Objective To investigate the expression and significance of bone morphogenetic protein-2 (BMP-2) in serum of ovarian cancer patients. Methods The serum levels of BMP-2 and CA125 in 51 patients with malignant ovarian tumors were detected by enzyme-linked immunosorbent assay (ELISA). Another 49 healthy women were selected as controls. Results The serum level of BMP-2 in ovarian epithelial carcinoma was significantly lower than that in the control group [(26.66 ± 8.68) pg / ml vs (39.34 ± 7.62) pg / ml], the difference was statistically significant (P <0.05). ROC curve analysis showed that the detection of serum BMP-2 had better sensitivity and specificity. Correlation analysis showed that the expression of BMP-2 in serum was negatively correlated with CA125 (r = -0.76, P <0.05). Conclusion The down-regulation of BMP-2 in serum of patients with ovarian cancer has important reference value for clinical diagnosis.